175 related articles for article (PubMed ID: 36155259)
21. Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis.
Li Y; Yang S; Li Z; Meng H; Jin W; Yang H; Yin W
J Transl Med; 2019 May; 17(1):168. PubMed ID: 31118027
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.
Liu Z; Tian S; Falo LD; Sakaguchi S; You Z
Mol Ther; 2009 Jul; 17(7):1274-81. PubMed ID: 19417739
[TBL] [Abstract][Full Text] [Related]
23. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
24. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
[TBL] [Abstract][Full Text] [Related]
25. GITR-GITRL system, a novel player in shock and inflammation.
Krausz LT; Bianchini R; Ronchetti S; Fettucciari K; Nocentini G; Riccardi C
ScientificWorldJournal; 2007 May; 7():533-66. PubMed ID: 17525820
[TBL] [Abstract][Full Text] [Related]
26. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
27. Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system.
Kobayashi Y; Kiguchi N; Fukazawa Y; Saika F; Maeda T; Kishioka S
J Biol Chem; 2015 May; 290(20):12603-13. PubMed ID: 25787078
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract][Full Text] [Related]
29. Simultaneously increased expression of glucocorticoid‑induced tumor necrosis factor receptor and its ligand contributes to increased interleukin‑5/13‑producing group 2 innate lymphocytes in murine asthma.
Zhang M; Wan J; Xu Y; Zhang D; Peng J; Qi C; Guo Q; Xia S; Su Z; Wang S; Xu H
Mol Med Rep; 2017 Jun; 15(6):4291-4299. PubMed ID: 28440511
[TBL] [Abstract][Full Text] [Related]
30. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
31. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
[TBL] [Abstract][Full Text] [Related]
32. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
[TBL] [Abstract][Full Text] [Related]
33. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
34. Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells.
Yu KY; Kim HS; Song SY; Min SS; Jeong JJ; Youn BS
Biochem Biophys Res Commun; 2003 Oct; 310(2):433-8. PubMed ID: 14521928
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R; Ballesteros-Merino C; Frye AK; Tran E; Rajamanickam V; Chang SC; Koguchi Y; Bifulco CB; Bernard B; Leidner RS; Curti BD; Fox BA; Urba WJ; Bell RB; Weinberg AD
Nat Commun; 2021 Feb; 12(1):1047. PubMed ID: 33594075
[TBL] [Abstract][Full Text] [Related]
37. GITR-expressing regulatory T-cell subsets are increased in tumor-positive lymph nodes from advanced breast cancer patients as compared to tumor-negative lymph nodes.
Krausz LT; Fischer-Fodor E; Major ZZ; Fetica B
Int J Immunopathol Pharmacol; 2012; 25(1):59-66. PubMed ID: 22507318
[TBL] [Abstract][Full Text] [Related]
38. Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma.
Giacomelli M; Monti M; Pezzola DC; Lonardi S; Bugatti M; Missale F; Cioncada R; Melocchi L; Giustini V; Villanacci V; Baronchelli C; Manenti S; Imberti L; Giurisato E; Vermi W
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370706
[TBL] [Abstract][Full Text] [Related]
39. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
